Paper40940901
Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance.
Leite LF and 9 others. Cancers (Basel), 2025. Cited by 26 papers, by iCite.
Cite this record
ConductScience Library. Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance. Papers, record 40940901. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40940901
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Anti-EGFR Therapy in Metastatic Colorectal Cancer: Identifying, Tracking, and Overcoming Resistance.
- PubMed
Topics0
NLM's MeSH indexing of the paper, its major topics first.
None in this release.
References157
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 20088793 | Molecular predictors of efficacy to anti-EGFR agents in colorectal cancer patients. | Curr Cancer Drug Targets | 2010 | https://conductscience.org/library/papers/20088793 | PubMed |
| 2 | 18392055 | Mutational analysis of oncogenic AKT E17K mutation in common solid cancers and acute leukaemias. | Br J Cancer | 2008 | https://conductscience.org/library/papers/18392055 | PubMed |
| 3 | 37243489 | Targeting the EGFR signaling pathway in cancer therapy: What's new in 2023? | Expert Opin Ther Targets | 2023 | https://conductscience.org/library/papers/37243489 | PubMed |
| 4 | 27907852 | The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. | Eur J Cancer | 2017 | https://conductscience.org/library/papers/27907852 | PubMed |
| 5 | 21900593 | Activation of ERBB2 signaling causes resistance to the EGFR-directed therapeutic antibody cetuximab. | Sci Transl Med | 2011 | https://conductscience.org/library/papers/21900593 | PubMed |
| 6 | 32988996 | Pertuzumab and trastuzumab emtansine in patients with HER2-amplified metastatic colorectal cancer: the phase II HERACLES-B trial. | ESMO Open | 2020 | https://conductscience.org/library/papers/32988996 | PubMed |
| 7 | 38473821 | Gluing GAP to RAS Mutants: A New Approach to an Old Problem in Cancer Drug Development. | Int J Mol Sci | 2024 | https://conductscience.org/library/papers/38473821 | PubMed |
| 8 | 37774394 | Anti-EGFR Antibodies in the Management of Advanced Colorectal Cancer. | Oncologist | 2023 | https://conductscience.org/library/papers/37774394 | PubMed |
| 9 | 37463037 | Impact of Anti-EGFR Therapies on HER2-Positive Metastatic Colorectal Cancer: A Systematic Literature Review and Meta-Analysis of Clinical Outcomes. | Oncologist | 2023 | https://conductscience.org/library/papers/37463037 | PubMed |
| 10 | 37071094 | Panitumumab vs Bevacizumab Added to Standard First-line Chemotherapy and Overall Survival Among Patients With RAS Wild-type, Left-Sided Metastatic Colorectal Cancer: A Randomized Clinical Trial. | JAMA | 2023 | https://conductscience.org/library/papers/37071094 | PubMed |
| 11 | 34830853 | Advantages and Challenges of Using ctDNA NGS to Assess the Presence of Minimal Residual Disease (MRD) in Solid Tumors. | Cancers (Basel) | 2021 | https://conductscience.org/library/papers/34830853 | PubMed |
| 12 | 27865140 | Overcoming dynamic molecular heterogeneity in metastatic colorectal cancer: Multikinase inhibition with regorafenib and the case of rechallenge with anti-EGFR. | Cancer Treat Rev | 2016 | https://conductscience.org/library/papers/27865140 | PubMed |
| 13 | 36419886 | Case Report: MAP2K1 K57N mutation is associated with primary resistance to anti-EGFR monoclonal antibodies in metastatic colorectal cancer. | Front Oncol | 2022 | https://conductscience.org/library/papers/36419886 | PubMed |
| 14 | 38711991 | Unveiling acquired resistance to anti-EGFR therapies in colorectal cancer: a long and winding road. | Front Pharmacol | 2024 | https://conductscience.org/library/papers/38711991 | PubMed |
| 15 | 18339877 | PIK3CA mutation/PTEN expression status predicts response of colon cancer cells to the epidermal growth factor receptor inhibitor cetuximab. | Cancer Res | 2008 | https://conductscience.org/library/papers/18339877 | PubMed |
| 16 | 39693606 | Antibody-Drug Conjugates Targeting the EGFR Ligand Epiregulin Elicit Robust Antitumor Activity in Colorectal Cancer. | Cancer Res | 2025 | https://conductscience.org/library/papers/39693606 | PubMed |
| 17 | 18223225 | Dose and schedule study of panitumumab monotherapy in patients with advanced solid malignancies. | Clin Cancer Res | 2008 | https://conductscience.org/library/papers/18223225 | PubMed |
| 18 | 36702949 | Combined PD-1, BRAF and MEK inhibition in BRAFV600E colorectal cancer: a phase 2 trial. | Nat Med | 2023 | https://conductscience.org/library/papers/36702949 | PubMed |
| 19 | 35427766 | EGFR signaling pathway as therapeutic target in human cancers. | Semin Cancer Biol | 2022 | https://conductscience.org/library/papers/35427766 | PubMed |
| 20 | 27345413 | FGFR3-TACC3 fusion proteins act as naturally occurring drivers of tumor resistance by functionally substituting for EGFR/ERK signaling. | Oncogene | 2017 | https://conductscience.org/library/papers/27345413 | PubMed |
Cited by27
The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 26 citations.
| PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|
| 42938848 | An Exploratory Study of ABT-806, a Tumor-Specific Anti-EGFR Antibody, in Subjects with Recurrent or Metastatic Head and Neck and Other Squamous Cell Carcinomas. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42938848 | PubMed |
| 42828116 | Colorectal Cancer: Epidemiology, Risk Factors, Signaling Pathways, Clinical Features, Screening, Diagnosis, and Management. | MedComm (2020) | 2026 | https://conductscience.org/library/papers/42828116 | PubMed |
| 42738319 | PIK3CA in Cancer: Structure, Biology, Alterations, and Actionability. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42738319 | PubMed |
| 42649986 | Biological and Targeted Therapies in the Multidisciplinary Management of Gastrointestinal Cancers. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42649986 | PubMed |
| 42635595 | EMB-01, an Anti-EGFR/c-MET Bispecific Antibody, in Patients with Heavily Pretreated Metastatic Colorectal Cancer from a Phase Ib/II, Open-Label, Multicenter Study. | Clin Cancer Res | 2026 | https://conductscience.org/library/papers/42635595 | PubMed |
| 42588741 | The Genetic Landscape of Colorectal Cancer: From Molecular Alterations to Therapeutic Decision Pathways. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588741 | PubMed |
| 42588722 | Targeting β-Adrenergic Signaling in Colorectal Cancer: Molecular Mechanisms and Therapeutic Potential of β-Blockers. | Cancers (Basel) | 2026 | https://conductscience.org/library/papers/42588722 | PubMed |
| 42515723 | Overcoming Resistance to Anti-EGFR Therapies: Mechanisms of Cetuximab and Panitumumab Resistance and Emerging Combination Strategies. | Pharmaceuticals (Basel) | 2026 | https://conductscience.org/library/papers/42515723 | PubMed |
| 42511923 | Enhancing Targeted Colorectal Cancer Therapies with Natural Products: Mechanistic Pathways. | Biomedicines | 2026 | https://conductscience.org/library/papers/42511923 | PubMed |
| 42240876 | Who Truly Benefits from Anti-EGFR Rechallenge in Metastatic Colorectal Cancer? From Clinical Enrichment to ctDNA-Guided Molecular Hyperselection. | J Gastrointest Cancer | 2026 | https://conductscience.org/library/papers/42240876 | PubMed |
| 42147347 | Common oncogenic mutations in colorectal cancer: drivers of carcinogenesis and potential therapeutic targets. | Front Pharmacol | 2026 | https://conductscience.org/library/papers/42147347 | PubMed |
| 42123533 | Liquid Biopsy in Colorectal Cancer: Future Perspectives Through the Lens of Artificial Intelligence-A Comprehensive Review of Novel Literature. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/42123533 | PubMed |
| 42074578 | Genomic Landscape, Targeted Therapies, and Mechanisms of Resistance in Molecularly Selected Metastatic Colorectal Cancer Patients. | Genes (Basel) | 2026 | https://conductscience.org/library/papers/42074578 | PubMed |
| 42022325 | Precision oncology in gynecologic cancers: molecular taxonomy, biomarker-guided therapeutics, and the challenge of therapeutic resistance. | Front Oncol | 2026 | https://conductscience.org/library/papers/42022325 | PubMed |
| 41977448 | EGFR Signaling in Colorectal Cancer: Novel Therapeutic Strategies, Predictive Biomarkers, and Counteracting Treatment Resistance. | Int J Mol Sci | 2026 | https://conductscience.org/library/papers/41977448 | PubMed |
| 41959919 | Risk of high-grade infections in colorectal cancer patients treated with anti-EGFR monoclonal antibodies: a meta-analysis of randomized controlled trials. | Front Oncol | 2026 | https://conductscience.org/library/papers/41959919 | PubMed |
| 41756334 | Clinical trials of bispecific antibody therapy for colorectal cancer: advanced and next steps. | Front Oncol | 2026 | https://conductscience.org/library/papers/41756334 | PubMed |
| 41742069 | ERBITAG: Non-interventional study on the efficacy of cetuximab in first-line therapy in patients with RAS wild-type metastatic colorectal cancer. | BMC Cancer | 2026 | https://conductscience.org/library/papers/41742069 | PubMed |
| 41670652 | Beyond the membrane: rethinking EGFR signaling in physiology and cancer. | Cell Mol Life Sci | 2026 | https://conductscience.org/library/papers/41670652 | PubMed |
| 41590540 | Comprehensive Landscape of Diagnostic, Prognostic and Predictive Biomarkers in Colorectal Cancer: From Genomics to Multi-Omics Integration in Precision Medicine. | J Pers Med | 2026 | https://conductscience.org/library/papers/41590540 | PubMed |
Genes6
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| AKT1 | 207 | PubTator's text mining | https://conductscience.org/library/genes/207 | NCBI Gene |
| BRAF | 673 | PubTator's text mining | https://conductscience.org/library/genes/673 | NCBI Gene |
| EGFR | 1956 | PubTator's text mining | https://conductscience.org/library/genes/1956 | NCBI Gene |
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| PIK3CB | 5291 | PubTator's text mining | https://conductscience.org/library/genes/5291 | NCBI Gene |
| SLTM | 79811 | PubTator's text mining | https://conductscience.org/library/genes/79811 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40940901
GET https://conductscience.org/api/papers/v1/40940901/references?page=2